Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Underperform rating

ME Staff
-
0

Analyst Ratings For Beigene Ltd (NASDAQ:BGNE)

Today, Macquarie initiated coverage on Beigene Ltd (NASDAQ:BGNE) with a Underperform.

There are 10 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on Beigene Ltd (NASDAQ:BGNE) is Buy with a consensus target price of $186.75 per share, a potential 44.60% upside.

Some recent analyst ratings include

  • 7/5/2019-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Underperform rating
  • 6/20/2019-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Piper Jaffray Companies
  • 6/4/2019-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Outperform ➝ Outperform rating and $201.00 price target
  • 5/31/2019-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Cowen with a $170.00 price target
  • 3/15/2019-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Buy ➝ Buy rating and $200.00 price target
  • On 7/1/2019 Xiaodong Wang, Insider, sold 4,847 with an average share price of $126.46 per share and the total transaction amounting to $612,951.62.
  • On 6/27/2019 Howard Liang, CFO, sold 5,876 with an average share price of $9.47 per share and the total transaction amounting to $55,645.72.
  • On 6/27/2019 Jane Huang, CMO, sold 430 with an average share price of $124.52 per share and the total transaction amounting to $53,543.60.
  • On 5/21/2019 Howard Liang, CFO, sold 23,200 with an average share price of $130.21 per share and the total transaction amounting to $3,020,872.00.
  • On 5/20/2019 Jane Huang, CMO, sold 300 with an average share price of $130.12 per share and the total transaction amounting to $39,036.00.
  • On 5/13/2019 Donald W Glazer, Director, sold 15,027 with an average share price of $125.11 per share and the total transaction amounting to $1,880,027.97.
  • On 5/6/2019 Howard Liang, CFO, sold 1,800 with an average share price of $130.01 per share and the total transaction amounting to $234,018.00.

About Beigene Ltd (NASDAQ:BGNE)
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. Read More…

Recent Trading Activity for Beigene Ltd (NASDAQ:BGNE)
Shares of Beigene Ltd closed the previous trading session at 129.15 −0.81 0.62% with shares trading hands.